Navigation Links
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
Date:8/2/2011

impact of CYP3A4 inhibition on LEVADEX pharmacokinetics. There were no drug related serious adverse events reported in any LEVADEX trial.  

About LEVADEX®

LEVADEX is an investigational drug for the acute treatment of migraine in adults, for which the Company has submitted a New Drug Application to the U.S. Food and Drug Administration. In the clinical trial, patients administered LEVADEX themselves using the proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE).  LEVADEX was evaluated in the efficacy portion of FREEDOM-301, MAP Pharmaceuticals' Phase 3 pivotal trial, which included 395 patients in the LEVADEX arm and 397 patients in the placebo arm.  In the Phase 3 trial, patients taking LEVADEX had statistically significant improvement at two hours compared to patients on placebo for all four co-primary endpoints:

  • Pain relief: 58.7 percent of patients who received LEVADEX compared with 34.5 percent for placebo (p<0.0001);
  • Phonophobia free: 52.9 percent of patients who received LEVADEX compared with 33.8 percent for placebo (p<0.0001);
  • Photophobia free: 46.6 percent of patients who received LEVADEX compared with 27.2 percent for placebo (p<0.0001); and
  • Nausea free: 67.1 percent of patients who received LEVADEX compared with 58.7 percent for placebo (p=0.02).

The most common adverse event reported in the trial was medication aftertaste at six percent versus two percent for placebo.  The next most common adverse event was nausea at five percent compared with two percent for placebo.  There were no decreases in lung function, as measured by spirometry, between the active and placebo groups. 

About Migraine

Migraine is estimated to occur in 18% of women and 6% of men in the United States.  Over 30 million people are impacted by the often debi
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., ... services, has launched the FreeRunner™ knee brace with ... suffer from patella mal-tracking return to active lifestyles. ... than other braces, providing support when patients need ... when they don,t. Patellofemoral issues are ...
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, Inc. ... announced it has completed the sale to Galderma of ... owned or held by Valeant for $1.4 billion in ... S.A, which recently completed its acquisition of Galderma. ... of our products to a company that is firmly ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
(Date:7/12/2014)... United Arab Emirates (PRWEB) July 12, 2014 ... another Los Angeles basketball legend is heading to the ... scorer and six-time champion will be in the UAE ... & Fitness Weekend in support of diabetes awareness. The ... an award-winning entertainment marketing and event management company based ...
(Date:7/12/2014)... Columbus, OH (PRWEB) July 12, 2014 Wright ... representing clients in Just For Men Lawsuits (case ... to inform consumers of reports that allege the popular hair ... serious chemical burns to their face, neck and other areas. ... of Just For Men chemical burns , the advertisements being ...
(Date:7/12/2014)... 12, 2014 Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
(Date:7/11/2014)... 12, 2014 Recently, MagicQuinceaneraDresses.com, the popular ... new collection of 2014 Quinceanera dresses . The ... want to look fashionable without paying a large amount ... up to 57% off. , The company’s online shop ... get amazing special occasion outfits. In addition to exquisite ...
(Date:7/11/2014)... 2014 According to new report ... is expected to register a CAGR of 2.28% ... 71 market data tables and 76 figures spread ... Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers will ... , The report provides market analysis of ...
Breaking Medicine News(10 mins):Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4
... Magnetic resonance imaging (MRI) findings in patients about to undergo ... that the cancer will return and spread post-treatment, according to ... journal Radiology. , This is the first study to show ... cancer outside the capsule of the prostate is an important ...
... have fewer symptoms of anxiety or depression, while children ... have difficulties forming relationships and being accepted by friends. ... and depression lead to the social problems, or vice ... likely to contribute to anxiety and depression than the ...
... toxic gas responsible for the unpleasant odor of rotten ... aspects of cardiovascular function in mice, producing a suspended-animation-like ... journal Anesthesiology, Massachusetts General Hospital (MGH) reseachers report that ... not depend on a reduction in body temperature and ...
... Responder For Saving Life of ... Femoral Artery, WALLINGFORD, Conn., March 24 Executives ... X. Hursey,Award to Rockland Paramedic Services (RPS) Medic 21 ... QuikClot(R) 1st Response(TM) brand,hemostatic agent to save the life ...
... WASHINGTON, March 24 The following are,remarks by Kent ... of World Tuberculosis Day 2008:, Although a cure ... a,century, TB remains one of three leading causes of ... million people each year,while HIV/AIDS claims more than two ...
... guidance, BOSTON, March 24 AMICAS, Inc. ... medical image and information management,solutions, announced today that ... to AMICAS, board of directors while accepting his ... In addition, the company,has promoted Kevin C. Burns ...
Cached Medicine News:Health News:MRI findings help forecast prostate cancer prognosis 2Health News:Youth's social problems contribute to anxiety and depression 2Health News:Sewer-gas-induced suspended animation is rapid and reversible 2Health News:NY-Area Paramedic Wins 2007 Francis X. Hursey Award for Heroic Use of QuikClot(R) Blood Clotting Product 2Health News:NY-Area Paramedic Wins 2007 Francis X. Hursey Award for Heroic Use of QuikClot(R) Blood Clotting Product 3Health News:Statement from Kent Hill, USAID Assistant Administrator for Global Health, on the Observance of World Tuberculosis Day 2008 2Health News:Statement from Kent Hill, USAID Assistant Administrator for Global Health, on the Observance of World Tuberculosis Day 2008 3Health News:AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer 2Health News:AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer 3Health News:AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer 4
Quantel Medical introduces the new Aviso A/B, a new generation high definition ultrasound system in a unique laptop or desktop PC workstation....
... Air Fluidized Therapy: ,Full-length air ... and provides greater comfort and accelerated ... system can be defluidized to facilitate ... Trendelenburg and Reverse Trendelenburg. CPR procedures ...
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
Medicine Products: